Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.
about
Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications.Incidence and risk of regorafenib-induced hepatotoxicity.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis.[Advanced gastrointestinal stromal tumors : What role does surgery currently play in multimodal concepts?].
P2860
Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Regorafenib treatment for adva ...... the UK managed access program.
@ast
Regorafenib treatment for adva ...... the UK managed access program.
@en
type
label
Regorafenib treatment for adva ...... the UK managed access program.
@ast
Regorafenib treatment for adva ...... the UK managed access program.
@en
prefLabel
Regorafenib treatment for adva ...... the UK managed access program.
@ast
Regorafenib treatment for adva ...... the UK managed access program.
@en
P2093
P2860
P356
P1476
Regorafenib treatment for adva ...... the UK managed access program.
@en
P2093
Aisha Miah
Alison Dunlop
Attila Kollàr
Beatrice Seddon
Charlotte Benson
Christina Messiou
Elisabeth Cartwright
Ellen McGrath
Ian Judson
Juan Martin-Liberal
P2860
P2888
P356
10.1186/2045-3329-4-17
P577
2014-12-04T00:00:00Z
P5875
P6179
1046743678